CD41, CD61 Antikörper (FITC)
Kurzübersicht für CD41, CD61 Antikörper (FITC) (ABIN2661406)
Target
Alle CD41, CD61 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Aufreinigung
- The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.
-
Isotyp
- IgM kappa
-
-
anti-CD41,CD61 antibody
Reaktivität: Human, Rind (Kuh) FACS, IP, ELISA, ICC Wirt: Maus Monoclonal IVA30 unconjugated
anti-CD41,CD61 (PAC-1 epitope) antibodyReaktivität: Human FACS, IP, ICC Wirt: Maus Monoclonal PAC-1 unconjugated
anti-CD41,CD61 (PAC-1 epitope) antibody (PE)Reaktivität: Human FACS Wirt: Maus Monoclonal PAC-1 PE
anti-CD41,CD61 (PAC-1 epitope) antibody (PerCP)Reaktivität: Human FACS Wirt: Maus Monoclonal PAC-1 PerCP
anti-CD41,CD61 antibodyReaktivität: Rind (Kuh), Schaf, Cat, Hund, Ziege, Pferd, Kaninchen FACS, IP, ELISA Wirt: Maus Monoclonal CO-35E4 unconjugated
anti-CD41,CD61 antibody (PE)Reaktivität: Huhn FACS Wirt: Maus Monoclonal 11C3 PE
anti-CD41,CD61 (PAC-1 epitope) antibody (FITC)Reaktivität: Human FACS Wirt: Maus Monoclonal PAC-1 FITC
anti-CD41,CD61 antibodyReaktivität: Human FACS, IF, DNA Mic Wirt: Maus Monoclonal A2A9-6 unconjugated
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Protect from prolonged exposure to light. Do not freeze.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- CD41, CD61 (CD41,CD61)
-
Andere Bezeichnung
- CD41/CD61
-
Hintergrund
- The gpIIb/IIIa complex, also known as integrin αIIbβ3, is expressed by megakaryocytes and platelets. It undergoes conformational changes upon activation by substances, such as ADP, thrombin, and TXA2, which subsequently reveals a ligand binding site that is specific for fibrinogen, von Willebrand factor (vWF), fibronectin, and vitronectin. This conformational change is crucial for platelet-platelet adhesion. Ligand bound gpIIb/IIIa complex promotes platelet aggregation. This complex plays an important role in hemostasis and is a target for developing therapeutic antibodies in immune thrombocytopenia.
Target
-
